Asterion Overview

  • Founded
  • 2000
Founded
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 2

Asterion General Information

Description

Developer of a novel therapeutic drug designed to help in the treatment of serious chronic and acute disorders. The company's drug is made by applying engineering techniques that have long-acting potent biopharmaceuticals that require frequent administration than existing marketed drugs, enabling patients to have improved healthcare outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • The Innovation Centre
  • 217 Portobello
  • Sheffield S1 4DP
  • England, United Kingdom
+44 0114 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Asterion Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 00.000 Completed Generating Revenue
4. Later Stage VC 26-Mar-2008 00000 00.000 Completed Generating Revenue
3. Later Stage VC 12-May-2006 00000 00000 Completed Generating Revenue
2. Later Stage VC 01-May-2006 Completed Startup
1. Seed Round 01-Feb-2001 Completed Startup
To view Asterion’s complete valuation and funding history, request access »

Asterion Executive Team (5)

Name Title Board Seat Contact Info
Richard Ross MD Chief Scientific Officer & Board Member
Peter Artymiuk Ph.D Founding Scientist and Head of Molecular Design
You’re viewing 2 of 5 executive team members. Get the full list »

Asterion Board Members (2)

Name Representing Role Since
Peter Grant Ph.D Self Board Member 000 0000
Richard Ross MD Asterion Chief Scientific Officer & Board Member 000 0000
To view Asterion’s complete board members history, request access »

Asterion Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
FusionIP Venture Capital Minority 000 0000 000000 0
IP Group Venture Capital Minority 000 0000 000000 0
To view Asterion’s complete investors history, request access »